Side effects of tirzepatide (Mounjaro®): what you need to know

Tirzepatide (Mounjaro) side effects: what you need to know
The short answer: The most common side effects of tirzepatide are nausea, diarrhea, and vomiting. These typically occur at the start of treatment, are temporary, and subside after 4–8 weeks thanks to the gradual dosing schedule.
Mounjaro® (tirzepatide) is rapidly establishing itself as one of the most effective weight-loss medications currently available. This drug acts simultaneously on two receptors: the GLP-1 receptor and the GIP receptor, which allows for greater weight loss than traditional GLP-1 medications. But it is precisely this dual action that raises valid questions about the side effects of tirzepatide. What can you expect? How long do these side effects last? And when should you see a doctor? You will find the answers in this article.
What are the most common side effects of Mounjaro?
The most common side effects of Mounjaro are gastrointestinal issues: nausea, diarrhea, vomiting, abdominal pain, and constipation. These occur in a significant portion of users, especially during the first few weeks or after increasing the dose. Technically, a loss of appetite is also a side effect, but most users consider it a desirable one.
The SURMOUNT-1 study showsthat nausea occurred in 28–39 percent of participants depending on the dose, and most cases were classified as mild or moderate. Diarrhea was observed in 17–23 percent of participants. In most cases, these symptoms resolved on their own as the body adjusted to the medication.
In addition, a slight increase in heart rate (3–5 beats per minute) was reported. This phenomenon is generally not clinically significant, but it requires special attention in individuals with heart disease.
How long do Mounjaro side effects last?
For most users, gastrointestinal side effects subside after four to eight weeks. Mounjaro's gradual dosing schedule is designed specifically for this purpose: treatment begins with a weekly dose of 2.5 mg, which is increased every four weeks to 5, 7.5, 10, 12.5, and finally up to 15 mg per week, as described in the Medication Guide .
Safety data from the Phase 3 study show that most side effects occurred during the first or second dose increase, after which they decreased significantly. The peak of symptoms therefore occurs at the beginning of treatment, not at the end.
Does tirzepatide cause serious side effects?
Serious side effects can occur, but they are rare. The most significant include acute pancreatitis, gallstones (cholelithiasis), and kidney issues resulting from dehydration caused by persistent vomiting or diarrhea. If a patient experiences severe and persistent abdominal pain that radiates to the back, they should always contact a doctor.
Thyroid tumors have been observed in animal studies, which has also been noted with other GLP-1-based medications. This has not yet been demonstrated in humans, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. The same applies to MEN2 syndrome (multiple endocrine neoplasia type 2).
Real-world studies showthat serious side effects are rare when the medication is used appropriately and monitoring is sufficient. Therefore, a careful review of the patient's medical history at the start of treatment is extremely important.
How do the side effects of Mounjaro differ from those of Ozempic and Wegovy?
Tirzepatide acts on two receptors, GLP-1 and GIP, which makes its effect both more potent and qualitatively different from that of semaglutide (Ozempic/Wegovy). The side effect profile is generally comparable, but at higher doses, gastrointestinal issues can be slightly more pronounced because the medication has a stronger effect on gastric emptying.
Comparative research showsthat tirzepatide led to significantly greater weight loss than 1 mg of weekly semaglutide in patients with type 2 diabetes, with a comparable safety profile. For more information, read about the differences between Mounjaro and Ozempic or explore the side effects of Ozempic.
The table below summarizes the key differences:
What can you do to reduce Mounjaro side effects?
The most effective way to limit side effects is to adjust your eating habits. Light, low-fat meals significantly reduce the risk of nausea. Avoid large portions, alcohol, and high-fat or sugary products, especially during the first few weeks after increasing your dose. Adequate fluid intake is essential, as diarrhea and vomiting can lead to dehydration.
Read more about diet during GLP-1 treatment and get practical tips on suitable food choices while using Mounjaro here. Some users experience fewer symptoms if they administer the injection just before bedtime, so the first few hours after the injection occur while sleeping. The timing of the dose and food choices together have a significant impact, especially during the first four weeks of treatment. Goodweigh actively supports you with every dose increase and adjusts your treatment plan if symptoms persist.
When should Mounjaro treatment be stopped due to side effects?
Stop treatment and contact a doctor immediately if you experience severe and persistent abdominal pain, especially if the pain radiates to your back. This may indicate acute pancreatitis. Jaundice or dark urine can be a sign of liver problems or gallstones. Severe dehydration is identified by dizziness, dark urine, and a reduced need to urinate.
Mild discomfort at the beginning of treatment is normal and expected. It is important to distinguish temporary discomfort related to a dose increase from symptoms that persist or worsen. If you have any doubts, please do not hesitate to contact us. Goodweigh provides medical monitoring throughout your entire treatment.
Mounjaro side effects are manageable with proper support
Most side effects of tirzepatide are mild, transient, and subside as you continue using the medication. Gradually increasing the dosage combined with dietary changes makes the treatment very tolerable for most patients. The SURMOUNT-2 study shows, and that even with long-term use at higher doses, the side effect profile remains acceptable.
Would you like to start Mounjaro treatment safely under medical supervision? With Goodweigh, you get an online consultation, a personalized dosage plan, and the peace of mind that comes with having a medical team to turn to if you have any questions or concerns. Discreet home delivery, with your entire treatment managed online.
Viitteet
- Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., ... & Wadden, T.A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Frías, J.P., Davies, M.J., Rosenstock, J., Pérez Manghi, F.C., Fernández Landó, L., Bergman, B.K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Garvey, W.T., Frias, J.P., Jastreboff, A.M., le Roux, C.W., Sattar, N., Aizenberg, D., ... & SURMOUNT-2 Investigators. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet, 402(10402), 613–626. https://pubmed.ncbi.nlm.nih.gov/37385275/
- Rosenstock, J., Wysham, C., Frías, J.P., Kaneko, S., Lee, C.J., Fernández Landó, L., ... & SURPASS-1 Investigators. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes (SURPASS-1). Lancet, 398(10295), 143–155. https://pubmed.ncbi.nlm.nih.gov/34186022/
- Thomsen, R.W., Pedersen, L., Hasvold, P., Sandbæk, A., & García Rodríguez, L.A. (2025). Concrete information on weight loss medications based on GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/40196933/
- Pharmacotherapy Guide. (2024). Tirzepatide. Dutch National Health Care Institute. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/tirzepatide



